home.social

#obesitytreatment — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #obesitytreatment, aggregated by home.social.

  1. Rhythm gets EU approval for IMCIVREE in rare obesity

    Rhythm Pharmaceuticals (NASDAQ: RYTM) announced the European Commission authorized IMCIVREE (setmelanotide) for treatment of obesity and control of…
    #Europe #EU #acquiredhypothalamicobesity #EuropeanCommissionauthorization #EuropeanUnion #IMCIVREE #obesitytreatment #Phase3TRANSCEND #raredisease #RhythmPharmaceuticals #RYTM
    europesays.com/europe/28270/

  2. Obese Seek Weight Loss Drugs Amidst Shifting Insurance Tides

    Insurance like Medicare and Medicaid are limiting coverage for weight loss drugs (Wegovy, Ozempic). Many obese patients now face higher costs or denied access.

    #WeightLossDrugs, #Ozempic, #Wegovy, #InsuranceCoverage, #ObesityTreatment

    newsletter.tf/weight-loss-drug

  3. Insurance coverage for popular weight loss drugs like Wegovy and Ozempic is becoming harder to get. This is different from last year when more people could access them for obesity.

    #WeightLossDrugs, #Ozempic, #Wegovy, #InsuranceCoverage, #ObesityTreatment
    newsletter.tf/weight-loss-drug

  4. Novo Nordisk's ADR rises 1.04% to $80.98 following UBS's positive assessment and buy recommendation, despite overall market decline, as competition in obesity treatment market intensifies.
    #YonhapInfomax #NovoNordisk #ADR #UBS #ObesityTreatment #GLP1 #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

  5. 🌍💊 Novo Nordisk's weight-loss drug Wegovy sees a massive 57% sales increase, doubling patient numbers to 2.2 million worldwide! The company anticipates up to 24% growth in 2025.
    pharmacy.biz/news/novo-nordisk

    More details here: pharmacy.biz 🏥 #Healthcare #ObesityTreatment #NovoNordisk

  6. The Dark Side of Weight Loss: GLP-1 RAs Linked to Increased Psychiatric Risks

    A groundbreaking study reveals a startling correlation between glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and heightened risks of depression, anxiety, and suicidal behavior in pat...

    news.lavx.hu/article/the-dark-

    #news #tech #GLP1RA #MentalHealth #ObesityTreatment

  7. The Dark Side of Weight Loss: GLP-1 RAs Linked to Increased Psychiatric Risks

    A groundbreaking study reveals a startling correlation between glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and heightened risks of depression, anxiety, and suicidal behavior in pat...

    news.lavx.hu/article/the-dark-

    #news #tech #GLP1RA #MentalHealth #ObesityTreatment

  8. The Dark Side of Weight Loss: GLP-1 RAs Linked to Increased Psychiatric Risks

    A groundbreaking study reveals a startling correlation between glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and heightened risks of depression, anxiety, and suicidal behavior in pat...

    news.lavx.hu/article/the-dark-

    #news #tech #GLP1RA #MentalHealth #ObesityTreatment

  9. The Dark Side of Weight Loss: GLP-1 RAs Linked to Increased Psychiatric Risks

    A groundbreaking study reveals a startling correlation between glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and heightened risks of depression, anxiety, and suicidal behavior in pat...

    news.lavx.hu/article/the-dark-

    #news #tech #GLP1RA #MentalHealth #ObesityTreatment

  10. The Dark Side of Weight Loss: GLP-1 RAs Linked to Increased Psychiatric Risks

    A groundbreaking study reveals a startling correlation between glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and heightened risks of depression, anxiety, and suicidal behavior in pat...

    news.lavx.hu/article/the-dark-

    #news #tech #GLP1RA #MentalHealth #ObesityTreatment